5-Amino-1MQ protocol

Standard

Weeks 1–2

12.5u

2.5 mg · Daily AM

Tolerance check. SC abdomen or thigh. Assess GI tolerance and stimulation before stepping up.

Weeks 3–8

25u

5 mg · Daily or twice a day

Working dose. Half-life 3.8–6.9 h, so splitting into two daily doses gives steadier NNMT inhibition. Hold here if Weeks 1–2 were comfortable.

Off

4 weeks

Standard cycle: 8 weeks on, 4 weeks off. Extended: 12 on, 6 off.

Phase	How often	Dose	Units	Notes
Weeks 1–2	Daily AM	2.5 mg	12.5u	Tolerance check. SC abdomen or thigh. Assess GI tolerance and stimulation before stepping up.
Weeks 3–8	Daily or twice a day	5 mg	25u	Working dose. Half-life 3.8–6.9 h, so splitting into two daily doses gives steadier NNMT inhibition. Hold here if Weeks 1–2 were comfortable.
Off	4 weeks	–	–	Standard cycle: 8 weeks on, 4 weeks off. Extended: 12 on, 6 off.

Cycle & timing

Cycle: 6–8 weeks on, 2–4 weeks off.

Timing: AM only, stimulating; avoid evening doses (sleep disruption).

Where: Abdomen or outer thigh.

What to expect

Mild appetite suppression and slight stimulation within 1–2 hours. Fat loss is gradual, most noticeable at 6–8 weeks with consistent caloric deficit.

How much to buy

For 8-wk @ 5 mg × 7/wk:

49

× 5mg vials

25

× 10mg vials

5

× 50mg vials

Men & women

Unisex metabolic (NNMT inhibitor), same protocol for men and women, no cycle effect.

Dilution calculator

Set to the guide's typical mix for 5-Amino-1MQ. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

25u

Volume

0.25 mL

Strength

20 mg/mL

Doses per vial

2

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
5 mg	0.25 mL	20 mg/mL
10 mg	0.50 mL	20 mg/mL
50 mg	2.5 mL	20 mg/mL

5 mg: 1 unit = 0.20 mg

Storage

PowderFreeze-dried: -4°F (up to 24 months).
MixedReconstituted: 36–46°F, use within 4 weeks. No freeze-thaw.

Don't use if: No human safety data; pregnancy, lactation, pediatrics excluded. · Active malignancy (NAD+ pathway interactions theoretical).

Stop if you notice

Persistent hypoglycemia
Unexplained fatigue
Mood changes

Side effects

Appetite suppression, mild stimulation, injection-site stinging.

Drug interactions

Metformin and berberine (additive AMPK activation, glucose drops); hard contraindication during the same dosing window.

Labs

Compound-specific: Fasting glucose (Week 0/4/8). Out of range? Rising glucose/HbA1c = blood sugar creeping up (recheck, adjust diet).

What these labs mean →

Warnings

NNMT inhibition broadly affects methylation. Long-term safety unknown.

Patient education

NAD+ pathway effects are theoretical based on cell and animal data.

These apply on top of the universal safety rules.

Pairs well with

NAD+

preserves injected NAD+ via NNMT inhibition

NAD+

MOTS-c

overlapping metabolic pathways

MOTS-c

Tirzepatide / Semaglutide

NNMT + GLP-1 synergy

Tirzepatide Semaglutide

Avoid with

Metformin or Berberine

additive AMPK activation risks significant glucose drops

Can 5-Amino-1MQ + NAD+ share a syringe?

Give it its own pin. NAD+ is a large volume with a slow push. Own pin, and never with copper or vitamin C.

What it does

Blocks NNMT enzyme to support fat metabolism, cellular energy, and NAD+ preservation. Inhibits Nicotinamide N-methyltransferase (NNMT), reducing NAD+ consumption and increasing SIRT1/AMPK activity.

Approved drug

Approved weight-loss drugs are far better proven: semaglutide (Wegovy), tirzepatide (Zepbound), orforglipron (Foundayo, oral, 2026), plus phentermine, Qsymia, Contrave and orlistat.

References

researchdosing peptidedosages PubMed thepeptidereport

From the guide, page 11.